-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
-
-
-
-
-
-
-
Rhythm Pharmaceuticals (RYTM) Acquires Xinvento B.V. and Portfolio of Investigational Therapeutics
-
-
-
-
-
-
-
After-Hours Stock Movers 06/16: Adobe Falls on Lower Guidance; U.S. Steel Rises on Higher Guidance (more...)
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Election of Jennifer Good to its Board of Directors
-
-
-
922,461 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All